Literature DB >> 23660237

Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform.

Ramakrishna S Sista1, Tong Wang, Ning Wu, Carrie Graham, Allen Eckhardt, Theodore Winger, Vijay Srinivasan, Deeksha Bali, David S Millington, Vamsee K Pamula.   

Abstract

PURPOSE: New therapies for lysosomal storage diseases (LSDs) have generated interest in screening newborns for these conditions. We present performance validation data on a digital microfluidic platform that performs multiplex enzymatic assays for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases.
METHODS: We developed an investigational disposable digital microfluidic cartridge that uses a single dried blood spot (DBS) punch for performing a 5-plex fluorometric enzymatic assay on up to 44 DBS samples. Precision and linearity of the assays were determined by analyzing quality control DBS samples; clinical performance was determined by analyzing 600 presumed normal and known affected samples (12 for Pompe, 7 for Fabry and 10 each for Hunter, Gaucher and Hurler).
RESULTS: Overall coefficient of variation (CV) values between cartridges, days, instruments, and operators ranged from 2 to 21%; linearity correlation coefficients were ≥0.98 for all assays. The multiplex enzymatic assay performed from a single DBS punch was able to discriminate presumed normal from known affected samples for 5 LSDs.
CONCLUSIONS: Digital microfluidic technology shows potential for rapid, high-throughput screening for 5 LSDs in a newborn screening laboratory environment. Sample preparation to enzymatic activity on each cartridge is less than 3h.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  4-MU; 4-MU-α-Gal; 4-MU-α-IDS; 4-MU-α-IDU; 4-MU-α-gluc; 4-MU-β-Gluc; 4-methyl umbelliferone; 4-methylumbelliferyl α-d-galactopyranoside; 4-methylumbelliferyl α-d-glucopyranoside; 4-methylumbelliferyl α-l-iduronate-2-sulfate; 4-methylumbelliferyl α-l-iduronide; 4-methylumbelliferyl β-d-glucopyranoside; ALL; CDC; CLSI; Centers for Disease Control and Prevention; Clinical and Laboratory Standards Institute; DBS; DMSO; Digital microfluidics; Dried blood spot; GAA; GBA; GLA; GalNac; High throughput; IDS; IDU; LSDs; Lysosomal storage disease; Multiplex enzymatic assay; N-acetyl-d-galactosamine; NBS; Newborn screening; QCBP; QCH; QCL; QCM; RFU; acid α-galactosidase; acid α-glucosidase; acid α-l-iduronate-2-sulfatase; acid α-l-iduronidase; acid β-d-glucosidase; advanced liquid logic, Inc.; d-Sac; d-saccharic acid 1,4 lactone; dimethyl sulfoxide; dried blood spot; lysosomal storage diseases; methyl-β-cyclodextrin; newborn screening; quality control base pool, 0% cord blood+100% leukoreduced adult blood adjusted to 50.5% hematocrit on filter paper; quality control high, cord blood adjusted to 50.5% hematocrit on filter paper; quality control low, 5% cord blood+95% leukoreduced adult blood adjusted to 50.5% hematocrit on filter paper; quality control medium, 50% cord blood+50% leukoreduced adult blood adjusted to 50.5% hematocrit on filter paper; relative fluorescence units; β-MBCD

Mesh:

Substances:

Year:  2013        PMID: 23660237      PMCID: PMC3926752          DOI: 10.1016/j.cca.2013.05.001

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  21 in total

1.  Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria.

Authors:  Thomas P Mechtler; Susanne Stary; Thomas F Metz; Víctor R De Jesús; Susanne Greber-Platzer; Arnold Pollak; Kurt R Herkner; Berthold Streubel; David C Kasper
Journal:  Lancet       Date:  2011-11-29       Impact factor: 79.321

2.  Rapid, single-step assay for Hunter syndrome in dried blood spots using digital microfluidics.

Authors:  Ramakrishna Sista; Allen E Eckhardt; Tong Wang; Márcia Séllos-Moura; Vamsee K Pamula
Journal:  Clin Chim Acta       Date:  2011-06-17       Impact factor: 3.786

3.  Newborn bloodspot screening for lysosomal storage disorders.

Authors:  Hui Zhou; Paul Fernhoff; Robert F Vogt
Journal:  J Pediatr       Date:  2011-04-13       Impact factor: 4.406

4.  Short-incubation mass spectrometry assay for lysosomal storage disorders in newborn and high-risk population screening.

Authors:  Thomas P Mechtler; Thomas F Metz; Hannes G Müller; Katharina Ostermann; Rene Ratschmann; Victor R De Jesus; Bori Shushan; Joseph M Di Bussolo; Joseph L Herman; Kurt R Herkner; David C Kasper
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-09-24       Impact factor: 3.205

5.  Newborn screening for lysosomal storage disorders.

Authors:  Peter J Meikle; Dallas J Grasby; Caroline J Dean; Debbie L Lang; Michelle Bockmann; Alison M Whittle; Michael J Fietz; Henrik Simonsen; Maria Fuller; Douglas A Brooks; John J Hopwood
Journal:  Mol Genet Metab       Date:  2006-04-04       Impact factor: 4.797

6.  Lysosomal storage disorder 4+1 multiplex assay for newborn screening using tandem mass spectrometry: application to a small-scale population study for five lysosomal storage disorders.

Authors:  Joseph J Orsini; Monica M Martin; Amanda L Showers; Olaf A Bodamer; X Kate Zhang; Michael H Gelb; Michele Caggana
Journal:  Clin Chim Acta       Date:  2012-04-21       Impact factor: 3.786

7.  A novel fluorometric enzyme analysis method for Hunter syndrome using dried blood spots.

Authors:  Adviye A Tolun; Carrie Graham; Qun Shi; Ramakrishna S Sista; Tong Wang; Allen E Eckhardt; Vamsee K Pamula; David S Millington; Deeksha S Bali
Journal:  Mol Genet Metab       Date:  2011-12-21       Impact factor: 4.797

8.  Simplified newborn screening protocol for lysosomal storage disorders.

Authors:  Thomas F Metz; Thomas P Mechtler; Joseph J Orsini; Monica Martin; Bori Shushan; Joseph L Herman; Rene Ratschmann; Chike B Item; Berthold Streubel; Kurt R Herkner; David C Kasper
Journal:  Clin Chem       Date:  2011-07-19       Impact factor: 8.327

9.  A tandem mass spectrometry triplex assay for the detection of Fabry, Pompe, and mucopolysaccharidosis-I (Hurler).

Authors:  Trisha A Duffey; Garland Bellamy; Susan Elliott; Angela C Fox; Michael Glass; Frantisek Turecek; Michael H Gelb; C Ronald Scott
Journal:  Clin Chem       Date:  2010-10-12       Impact factor: 8.327

10.  Digital microfluidic platform for multiplexing enzyme assays: implications for lysosomal storage disease screening in newborns.

Authors:  Ramakrishna S Sista; Allen E Eckhardt; Tong Wang; Carrie Graham; Jeremy L Rouse; Scott M Norton; Vijay Srinivasan; Michael G Pollack; Adviye A Tolun; Deeksha Bali; David S Millington; Vamsee K Pamula
Journal:  Clin Chem       Date:  2011-08-22       Impact factor: 8.327

View more
  29 in total

1.  Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.

Authors:  Na Lin; Jingyu Huang; Sara Violante; Joseph J Orsini; Michele Caggana; Erin E Hughes; Colleen Stevens; Lisa DiAntonio; Hsuan Chieh Liao; Xinying Hong; Farideh Ghomashchi; Arun Babu Kumar; Hui Zhou; Ruth Kornreich; Melissa Wasserstein; Michael H Gelb; Chunli Yu
Journal:  Clin Chem       Date:  2017-02-14       Impact factor: 8.327

Review 2.  Newborn Screening for Lysosomal Storage Disorders.

Authors:  Roy W A Peake; Olaf A Bodamer
Journal:  J Pediatr Genet       Date:  2016-12-02

Review 3.  Newborn screening of mucopolysaccharidoses: past, present, and future.

Authors:  Nivethitha Arunkumar; Thomas J Langan; Molly Stapleton; Francyne Kubaski; Robert W Mason; Rajendra Singh; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Toshiyuki Fukao; Shunji Tomatsu
Journal:  J Hum Genet       Date:  2020-04-10       Impact factor: 3.172

4.  Incidence of 4 Lysosomal Storage Disorders From 4 Years of Newborn Screening.

Authors:  Patrick V Hopkins; Tracy Klug; Lacey Vermette; Julie Raburn-Miller; Jami Kiesling; Sharmini Rogers
Journal:  JAMA Pediatr       Date:  2018-07-01       Impact factor: 16.193

Review 5.  Lysosomal diseases: diagnostic update.

Authors:  Bryan Winchester
Journal:  J Inherit Metab Dis       Date:  2014-04-08       Impact factor: 4.982

6.  One-step synthesis of carbon-13-labeled globotriaosylsphingosine (lyso-Gb3), an internal standard for biomarker analysis of Fabry disease.

Authors:  Xinying Hong; Michael H Gelb
Journal:  Mol Genet Metab       Date:  2018-08-10       Impact factor: 4.797

Review 7.  Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders.

Authors:  Monique Piraud; Magali Pettazzoni; Pamela Lavoie; Séverine Ruet; Cécile Pagan; David Cheillan; Philippe Latour; Christine Vianey-Saban; Christiane Auray-Blais; Roseline Froissart
Journal:  J Inherit Metab Dis       Date:  2018-03-19       Impact factor: 4.982

Review 8.  Pompe disease: literature review and case series.

Authors:  Majed Dasouki; Omar Jawdat; Osama Almadhoun; Mamatha Pasnoor; April L McVey; Ahmad Abuzinadah; Laura Herbelin; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

9.  Enzymatic Screening and Diagnosis of Lysosomal Storage Diseases.

Authors:  Chunli Yu; Qin Sun; Hui Zhou
Journal:  N Am J Med Sci (Boston)       Date:  2013

10.  Point-of-Care Quantitative Measure of Glucose-6-Phosphate Dehydrogenase Enzyme Deficiency.

Authors:  Vinod K Bhutani; Michael Kaplan; Bertil Glader; Michael Cotten; Jairus Kleinert; Vamsee Pamula
Journal:  Pediatrics       Date:  2015-10-12       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.